Sector News

David Meline, Amgen’s Chief Financial Officer, to retire

October 23, 2019
Life sciences

Amgen today announced the planned retirement of David W. Meline, who has served as the company’s executive vice president and chief financial officer (CFO) since 2014. Meline will serve as CFO through the end of 2019 and remain at the company into the second quarter of 2020 to help ensure a smooth transition of his responsibilities. The company also announced that Peter H. Griffith has joined Amgen as executive vice president, Finance, and will be Meline’s successor as CFO as of Jan. 1, 2020.

“I am grateful to David for the many contributions he has made to Amgen’s success,” said Robert A. Bradway, chairman and chief executive officer. “David has played an essential role in the enterprise-wide transformation that has enabled Amgen to deliver outstanding financial performance to our shareholders, while also investing heavily in new product launches, research and development, and global expansion. Additionally, under David’s leadership, Amgen has built and embedded a set of productivity capabilities throughout our organization that position us for continued success in a highly dynamic external environment.”

Meline joined Amgen from 3M, where he was senior vice president and CFO. Previously, Meline held numerous senior-level roles at General Motors, including vice president and CFO for GM North America.

“A hallmark of Amgen’s nearly 40-year history has been well-planned transitions of key leadership roles,” Bradway said. “I am delighted to welcome Peter to Amgen. His extensive global experience and financial skills will be instrumental to our strategy for investing in innovation to drive long-term growth. I am pleased that David will remain with Amgen into 2020 to work with Peter and ensure a smooth transition.”

Griffith joins Amgen from Sherwood Canyon Group, LLC, a private equity and advisory firm, where he served as president. Previously, he retired from EY (formerly Ernst & Young), a leader in assurance, tax, transaction and advisory services, after a distinguished career there, including almost 22 years as a partner. Most recently, Griffith served as EY’s Global Vice Chair, Corporate Development with responsibility for driving the firm’s international growth and expanding its capabilities worldwide. He previously served as EY’s Global Managing Partner, Finance and Corporate Development and, before that, as Global Managing Partner, Operations and Finance during a time when the organization grew annual revenues more than 25% to over $27 billion. This latter role included the Finance and Accounting, Corporate Development, Tax, and Treasury functions. During his tenure, Griffith served on the EY Global Executive Board, the EY Americas Executive Board, and the Executive Board of Ernst & Young LLP. Prior to EY, he was Managing Director and Head of Investment Banking at Wedbush Securities.

Source: Amgen

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”